Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family
Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family
The Competitive Intelligence Report Inhibitors of the bromodomain and extra-terminal domain (BET) family as of January 201 provides a competitor analysis in the development pipeline of novel small molecule pan, selective or dual target bromodomain and extra-terminal domain (BET) family inhibitors suitable for treatment of cancer, inflammatory and cardiovascular diseases. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Bromodomains are epigenetic readers of histone acetylation involved in chromatin remodeling and transcriptional regulation. Bromodomains have attracted great interest as promising new epigenetic targets for diverse human diseases, including inflammation, cancer, and cardiovascular disease. The demonstration that two small molecule compounds, JQ1 and I-BET762, potently inhibit proteins of the bromodomain and extra-terminal (BET) family with potential for cancer and inflammatory disease sparked intense efforts in academia and pharmaceutical industry to develop novel bromodomain antagonists for therapeutic applications. Several BET inhibitors are already in clinical trials for hematological malignancies, solid tumors and cardiovascular disease.
The report includes a compilation of currently active projects in research and development of novel small molecules targeting for treatment of hematologic malignancies, solid tumors, inflammatory and cardiovascular diseases. In addition, the report lists company-specific RD pipelines of BET Inhibitors. Competitor projects are listed in a tabular format providing Information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of RD projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The Competitive Intelligence Report Inhibitors of the bromodomain and extra-terminal domain (BET) family as of January 201 provides a competitor analysis in the development pipeline of novel small molecule pan, selective or dual target bromodomain and extra-terminal domain (BET) family inhibitors suitable for treatment of cancer, inflammatory and cardiovascular diseases. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Bromodomains are epigenetic readers of histone acetylation involved in chromatin remodeling and transcriptional regulation. Bromodomains have attracted great interest as promising new epigenetic targets for diverse human diseases, including inflammation, cancer, and cardiovascular disease. The demonstration that two small molecule compounds, JQ1 and I-BET762, potently inhibit proteins of the bromodomain and extra-terminal (BET) family with potential for cancer and inflammatory disease sparked intense efforts in academia and pharmaceutical industry to develop novel bromodomain antagonists for therapeutic applications. Several BET inhibitors are already in clinical trials for hematological malignancies, solid tumors and cardiovascular disease.
The report includes a compilation of currently active projects in research and development of novel small molecules targeting for treatment of hematologic malignancies, solid tumors, inflammatory and cardiovascular diseases. In addition, the report lists company-specific RD pipelines of BET Inhibitors. Competitor projects are listed in a tabular format providing Information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product category/Therapeutic Area,
- Indication,
- RD Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of RD projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family
Table of Contents
Table of Contents
- Inhibitors of the bromodomain and extra-terminal domain (BET) family
- Corporate BET Inhibitor R&D Pipelines
